Amyloid proteotoxicity initiates an inflammatory response blocked by cannabinoids

npj Aging and Mechanisms of Disease

Volumn 2, Issue 1, 2016, Pages

  Currais, Antonio ^a   Quehenberger, Oswald ^b,c   Armando, Aaron M ^b   Daugherty, Daniel ^a   Maher, Pam ^a   Schubert, David ^a  

^a SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85027581474     PISSN: None     EISSN: 20563973     Source Type: Journal    
DOI: 10.1038/npjamd.2016.12     Document Type: Article

References (50)

1. Prior, M. et al. Back to the future with phenotypic screening. ACS Chem. Neurosci. 5, 503–513 (2014).
2. Simonsen, A. et al. Promoting basal levels of autophagy in the nervous system enhances longevity and oxidant resistance in adult Drosophila. Autophagy 4, 176–184 (2008).
3. Bayer, T. A. & Wirths, O. Intracellular accumulation of amyloid-Beta—a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease. Front. Aging Neurosci. 2, 8 (2010).
4. Lauritzen, I. et al. The beta-secretase-derived C-terminal fragment of betaAPP, C99, but not Abeta, is a key contributor to early intraneuronal lesions in triple-transgenic mouse hippocampus. J. Neurosci. 32, 16243–16255a (2012).
5. Tampellini, D. et al. Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice. J. Neurosci. 30, 14299–14304 (2010).
6. Wirths, O. et al. Intraneuronal Abeta accumulation precedes plaque formation in beta-amyloid precursor protein and presenilin-1 double-transgenic mice. Neurosci. Lett. 306, 116–120 (2001).
7. Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L. & LaFerla, F. M. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45, 675–688 (2005).
8. Gouras, G. K., Almeida, C. G. & Takahashi, R. H. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol. Aging 26, 1235–1244 (2005).
9. Li, W. et al. Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation. J. Neurosci. 24, 7400–7409 (2004).
10. Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R. & Finkbeiner, S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805–810 (2004).
11. Ransohoff, R. M. & Brown, M. A. Innate immunity in the central nervous system. J. Clin. Invest. 122, 1164–1171 (2012).
12. Sopher, B. L. et al. Cytotoxicity mediated by conditional expression of a carboxyl-terminal derivative of the beta-amyloid precursor protein. Brain Res. Mol. Brain Res. 26, 207–217 (1994).
13. Elinder, F. et al. Opening of plasma membrane voltage-dependent anion channels (VDAC) precedes caspase activation in neuronal apoptosis induced by toxic stimuli. Cell Death Differ. 12, 1134–1140 (2005).
14. Valera, E., Dargusch, R., Maher, P. A. & Schubert, D. Modulation of 5-lipoxygenase in proteotoxicity and Alzheimer's disease. J. Neurosci. 33, 10512–10525 (2013).
15. Olgiati, P., Politis, A. M., Papadimitriou, G. N., De Ronchi, D. & Serretti, A. Genetics of late-onset Alzheimer's disease: update from the alzgene database and analysis of shared pathways. Int. J. Alzheimers Dis. 2011, 832379 (2011).
16. Pan, W. & Kastin, A. J. Interactions of cytokines with the blood-brain barrier: implications for feeding. Curr. Pharm Des. 9, 827–831 (2003).
17. Denes, A., Lopez-Castejon, G. & Brough, D. Caspase-1: is IL-1 just the tip of the ICEberg? Cell Death Dis 3, e338 (2012).
18. FitzGerald, G. A. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat. Rev. Drug Discov. 2, 879–890 (2003).
19. Radmark, O., Werz, O., Steinhilber, D. & Samuelsson, B. 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem. Sci. 32, 332–341 (2007).
20. Chen, H., Dzitoyeva, S. & Manev, H. 5-Lipoxygenase in mouse cerebellar Purkinje cells. Neuroscience 171, 383–389 (2010).
21. Sanchez-Mejia, R. O. & Mucke, L. Phospholipase A2 and arachidonic acid in Alzheimer's disease. Biochim. Biophys. Acta 1801, 784–790 (2010).
22. Sanchez-Mejia, R. O. et al. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat. Neurosci. 11, 1311–1318 (2008).
23. Hope, W. C., Chen, T. & Morgan, D. W. Secretory phospholipase A2 inhibitors and calmodulin antagonists as inhibitors of cytosolic phospholipase A2. Agents Actions 39 Spec No, C39–C42 (1993).
24. Veldhuis, W. B. et al. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases. J. Neurosci. 23, 4127–4133 (2003).
25. Ott, C. et al. Role of advanced glycation end products in cellular signaling. Redox Biol. 2, 411–429 (2014).
26. Wright, A. L. et al. Neuroinflammation and neuronal loss precede Abeta plaque deposition in the hAPP-J20 mouse model of Alzheimer's disease. PLoS ONE 8, e59586 (2013).
27. Howcroft, T. K. et al. The role of inflammation in age-related disease. Aging (Albany NY) 5, 84–93 (2013).
28. Rubio-Perez, J. M. & Morillas-Ruiz, J. M. A review: inflammatory process in Alzheimer's disease, role of cytokines. Sci. World J. 2012, 756357 (2012).
29. Lampron, A., Elali, A. & Rivest, S. Innate immunity in the CNS: redefining the relationship between the CNS and Its environment. Neuron 78, 214–232 (2013).
30. Wyss-Coray, T. & Mucke, L. Inflammation in neurodegenerative disease--A double-edged sword. Neuron 35, 419–432 (2002).
31. Hanzel, C. E. et al. Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease. Neurobiol. Aging 35, 2249–2262 (2014).
32. Zandi, P. P. et al. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology 59, 880–886 (2002).
33. Aisen, P. S. et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289, 2819–2826 (2003).
34. Ahmad, A. S., Ahmad, M., Maruyama, T., Narumiya, S. & Dore, S. Prostaglandin D2 DP1 receptor is beneficial in ischemic stroke and in acute exicitotoxicity in young and old mice. Age (Dordr) 32, 271–282 (2010).
35. Kitamura, Y. et al. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 254, 582–586 (1999).
36. Saleem, S. et al. PGD(2) DP1 receptor protects brain from ischemia-reperfusion injury. Eur. J. Neurosci. 26, 73–78 (2007).
37. Cazevieille, C., Muller, A., Meynier, F., Dutrait, N. & Bonne, C. Protection by prostaglandins from glutamate toxicity in cortical neurons. Neurochem. Int. 24, 395–398 (1994).
38. Kim, E. J. et al. Neuroprotective effects of prostaglandin E2 or cAMP against microglial and neuronal free radical mediated toxicity associated with inflammation. J. Neurosci. Res. 70, 97–107 (2002).
39. McCullough, L. et al. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J. Neurosci. 24, 257–268 (2004).
40. Di Meco, A., Lauretti, E., Vagnozzi, A. N. & Pratico, D. Zileuton restores memory impairments and reverses amyloid and tau pathology in aged Alzheimer's disease mice. Neurobiol. Aging 35, 2458–2464 (2014).
41. Currais, A. et al. Modulation of p25 and inflammatory pathways by Fisetin Maintains cognitive function in Alzheimer's disease transgenic mice. Aging Cell 13, 379–390 (2014).
42. Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805–820 (2010).
43. Yan, W. et al. High-mobility group box 1 activates caspase-1 and promotes hepatocellular carcinoma invasiveness and metastases. Hepatology 55, 1863–1875 (2012).
44. Stella, N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58, 1017–1030 (2010).
45. McEwen, B. S. et al. Mechanisms of stress in the brain. Nat. Neurosci. 18, 1353–1363 (2015).
46. Campbell, V. A. & Gowran, A. Alzheimer's disease; taking the edge off with cannabinoids? Br. J. Pharmacol. 152, 655–662 (2007).
47. Martin-Moreno, A. M. et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J. Neuroinflamm. 9, 8 (2012).
48. Aiken, C. T., Tobin, A. J. & Schweitzer, E. S. A cell-based screen for drugs to treat Huntington's disease. Neurobiol. Dis. 16, 546–555 (2004).
49. Burstein, S. H. & Zurier, R. B. Cannabinoids, endocannabinoids, and related analogs in inflammation. AAPS J 11, 109–119 (2009).
50. Turcotte, C., Chouinard, F., Lefebvre, J. S. & Flamand, N. Regulation of inflammation by cannabinoids, the endocannabinoids 2-arachidonoyl-glycerol and arachidonoyl-ethanolamide, and their metabolites. J. Leukoc. Biol. 97, 1049–1070 (2015).